Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

Global Allogeneic T Cell Therapies Market Outlook

The global allogeneic T cell therapies market size is anticipated to grow at a CAGR of 9.75% during the forecast period of 2024-2032, driven by the rising prevalence of cancer cases across the globe.

Allogeneic T Cell Therapies: Introduction

Allogeneic or universal cell therapies rely on a single source of cells to treat patients. Cells are collected from a healthy person’s body and directly transferred into the patient’s body or developed into a master cell bank (MCB). There are several advantages of using allogenic treatments and one of them is easy availability of cells and tissues. However, allogeneic treatments may also be responsible for transmitting infections or diseases. The use of allogeneic cell therapy is majorly performed in patients whose own stems cells cannot be transplanted, such as people suffering from leukemia.

Global Allogeneic T Cell Therapies Market Analysis

The prevalence of chronic diseases like cancer has been increasing rapidly owing to the unhealthy lifestyles and carcinogenic environment, among other factors. The awareness about the importance of getting a timely treatment for cancer is also growing among the population. This has increased the need for advanced and efficient treatments and therapies, including allogeneic T cell therapies. With the rising number of patients opting for timely treatments owing to the advanced diagnostic tests and treatments available for cancer, the demand for allogeneic T cell therapies is likely to grow further in the coming years. Allogeneic T cell therapies have gained significant popularity among oncologists as they offer efficient benefits to the patient in fighting the cancer cells.

Governments of several countries are taking initiatives to improve their healthcare systems in order to provide the best treatment to the patients with an overall enhanced patient experience. The increasing number of research and development activities for allogeneic T-cell therapy significantly adds to the global allogeneic T cell therapy market growth. Recent research has exhibited the advancement of Chimeric antigen receptor (CAR) T cell therapy, which was previously used for treating blood cancers like leukemia, lymphoma, and multiple myeloma. It has now shown effective action against solid tumours from lung cancer to kidney cancer to bone cancer as well.

The increasing number of approvals is also influencing the market growth. For example, six CAR T cell therapies that demonstrated efficacy in patients with B-cell malignancies and multiple myeloma, which was never seen before, have been approved officially. Additionally, the increasing investment by pharmaceutical companies are also likely to add significantly to the global allogeneic T cell therapy market share.

The increasing collaborations among the key players are also aiding the growth of the market. For instance, a collaboration between HaemaLogiX and Peter MacCallum Cancer Centre took place in August 2024, which is expected to result in the advancement of KMA, Kappa Myeloma Antigen, which is a receptor solely appearing on myeloma cells in kappa-type MM.

Global Allogeneic T Cell Therapies Market Segmentations

Market Breakup by Product Type

• Chimeric Antigen Receptor (CAR) T Cell Therapies

• T Cell Receptor (TCR) Therapies

• Others

Market Breakup by Therapeutics Indications

• Cancer

• Autoimmune Diseases

• Infectious Diseases

• Others

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Research Institutes

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Allogeneic T Cell Therapies Market Overview

The growth of the global market for allogeneic T cell therapy is driven by the rising accessibility of gene therapies in the market. The growth is also driven by the rising geriatric and paediatric patient population, and the increasing prevalence of chronic diseases, such as cancer. The rising awareness about gene cell therapies and its benefits are further aiding the market demand. Due to the increasing awareness, the demand for effective gene and cell treatment therapies is also increasing, further propelling the global allogeneic T cell therapy market value. The expenditure against T cell therapies is also rising, which is likely to provide further impetus to the growth of the market.

Allogeneic T Cell Therapies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Athersys Inc. 

• Mesoblast Ltd.

• Biorestorative Therapies Inc.

• Pluristem Inc.

• Brainstorm Cell Limited.

• ViaCyte Inc.

• Gamida Cell

• HOPE BIOSCIENCES

• Cellular Biomedicine Group 

• Smith+Nephew 

• MEDIPOST 

• ANTEROGEN.CO, LTD. 

• NuVasive Inc. 

• RTI Surgical 

• AlloSource 

• JCR Pharmaceuticals Co. Ltd. 

• Takeda Pharmaceutical Company Limited

Key Highlights of the Report